Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:
BioSphere Medical Inc. (NSDQ:BSMD) managed to cut its losses in half during 2009, ending the year with a 7 percent sales increase.
The Rockland, Mass.-based microsphere maker reported a net loss of $293,000 on $8.4 million in sales during the three months ended Dec. 31, 2009, compared to a $1.7 million loss on $7.2 million in sales for the same period in 2008.
Varian Medical Systems (NYSE:VAR) posted first-quarter sales of $540.9 million, up 6.3 percent compared with $508.7 million during the same period last year. Net earnings rose 14.5 percent to $78.8 million, compared with $68.8 million during Q1:
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2010
Net earnings per diluted share from continuing operations rise 13 percent to $0.63; revenues rise 6 percent to $541 million; company raises guidance for fiscal year
Perceptive Informatics tapped a lymphoma expert from Georgetown University Hospital for its scientific advisory board.
The Boston-based Parexel International Corp. (NSDQ:PRXL) subsidiary, which makes software to manage medical imaging data for clinical trials, named Dr. Bruce Cheson to its medical imaging scientific advisor team. Cheson leads the hematology program at Georgetown’s Lombardi Comprehensive Cancer Center and is an expert on lymphoma treatment.
Hologic Inc. (NSDQ:HOLX) lost a patent battle with SenoRx Inc. (NSDQ:SENO), after a California jury ruled a pair of Hologic patents invalid.
In a lawsuit filed late last year, Bedford, Mass.-based Hologic accused SenoRx of infringing two patents covering Hologic’s MammoSite breast cancer radiation therapy system with its Contura device. But a jury in the U.S. District Court for Northern California decided that both patents were invalid and that, in any case, Aliso Viejo, Calif.-based SenoRx didn’t violate one of them.
Hologic said it plans to appeal the decision to the Court of Appeals for the Federal Circuit.
A jury trial is under way in a lawsuit filed last year by Hologic Inc. (NSDQ:HOLX) against SenoRx (NSDQ:SENO), alleging that SenoRx infringed patents covering Hologic’s MammoSite breast cancer radiation therapy system with its Contura device.
On-Q-ity raised $21 million in a Series A round to develop blood-based diagnostics used to monitor treatment of cancer patients.
The Waltham, Mass.-based firm raised the cash from venture backers including Bessemer Venture Partners, Physic Ventures and Northgate Capital, led by MDV-Mohr Davidow — which drove the creation of the company from a pair of venture-backed firms that couldn’t raise their Series B rounds last summer, according to the PE Hub blog.
BioSphere Medical Inc. continued to boost sales and cut expenses as it moved closer to the break-even point during the third quarter.
The Rockland, Mass.-based microsphere maker posted sales of $7.7 million during the three months ended Sept. 30, up 6.8 percent compared with the same period last year. Net losses narrowed 84.6 percent to $216,000, compared with net losses of $1.4 million during the third quarter of 2008.
BioSphere Medical Inc. wants the Food & Drug Administration to OK a clinical trial of its QuadraSphere liver cancer treatment.
The Rockland, Mass.-based microsphere maker said it’s asked the federal watchdog agency for an investigational device exemption to study whether its microspheres can be combined with the chemotherapeutic agent doxorubicin to effectively treat liver cancer.
Nuclea Biotherapies LLC, an oncology diagnostics company with offices in Pittsfield and Worcheser, Mass., wrapped up a $3.4 million funding round, according to regulatory documents filed Thursday with the U.S. Securities and Exchange Commission.
In July the company said it had closed on $1 million in new financing through the sale of preferred stock units. Since that time, three additional investor groups came aboard, including New York’s Private Equity Investors Fund.